Pacira Biosciences Inc. (PCRX)

36.54
1.40 3.69
NASDAQ : Health Technology
Prev Close 37.94
Open 37.93
Day Low/High 36.40 / 38.15
52 Wk Low/High 35.07 / 55.00
Volume 615.32K
Avg Volume 501.40K
Exchange NASDAQ
Shares Outstanding 41.63M
Market Cap 1.64B
P/E Ratio 207.26
Div & Yield N.A. (N.A)
New Lifetime High Today: Pacira Pharmaceuticals (PCRX)

New Lifetime High Today: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Pacira Pharmaceuticals, Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2014 Life Sciences...

Fitz Bits: Buying Opportunity This Week

Fitz Bits: Buying Opportunity This Week

After moves like last week, buyers tend to nibble.

Pacira Pharmaceuticals (PCRX) Hits New Lifetime High

Pacira Pharmaceuticals (PCRX) Hits New Lifetime High

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue Up 31% Over First Quarter

Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue Up 31% Over First Quarter

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced...

Pacira Pharmaceuticals Announces Timing For Second Quarter 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals Announces Timing For Second Quarter 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2014, will be released before the market opens on Thursday, July 31, 2014.

Pacira Pharmaceuticals, Inc. Announces Publication Of Pooled Results From IMPROVE Studies Evaluating Health Economic Benefits Of EXPAREL®

Pacira Pharmaceuticals, Inc. Announces Publication Of Pooled Results From IMPROVE Studies Evaluating Health Economic Benefits Of EXPAREL®

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies designed to compare postsurgical narcotic use and ...

Pacira Pharmaceuticals (PCRX) Reaches New Lifetime High Today

Pacira Pharmaceuticals (PCRX) Reaches New Lifetime High Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Use Options For a Chance To Buy PCRX at a 30% Discount

Use Options For a Chance To Buy PCRX at a 30% Discount

Looking back to 66 days ago, Pacira Pharmaceuticals Inc. priced a 1,600,000 share secondary stock offering at $64.00 per share.

Know When to Walk Away

Know When to Walk Away

When warranted, remind yourself there will be other days to trade.

Pacira Pharmaceuticals, Inc. To Present At June Investor Conferences

Pacira Pharmaceuticals, Inc. To Present At June Investor Conferences

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at ...

Insider Trading Alert - ENS, HOS And PCRX Traded By Insiders

Insider Trading Alert - ENS, HOS And PCRX Traded By Insiders

Stocks with insider trader activity include ENS, HOS and PCRX

Use Options For a Chance To Buy PCRX at a 25% Discount

Use Options For a Chance To Buy PCRX at a 25% Discount

Looking back to 31 days ago, Pacira Pharmaceuticals priced a 1,600,000 share secondary stock offering at $64.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Friday, the stock is now 13.8% above the offering price.

Insider Trading Alert - BLL, PCRX And TIBX Traded By Insiders

Insider Trading Alert - BLL, PCRX And TIBX Traded By Insiders

Stocks with insider trader activity include BLL, PCRX and TIBX

Pacira Pharmaceuticals, Inc. Announces SNDA Submission For EXPAREL Nerve Block Indication

Pacira Pharmaceuticals, Inc. Announces SNDA Submission For EXPAREL Nerve Block Indication

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.

'Fast Money' Recap: Financial Sector Follies

'Fast Money' Recap: Financial Sector Follies

The trading panel discussed which stocks have done well and which have not.

Pacira Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference

Pacira Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill ...

Three Potential Breakouts

Three Potential Breakouts

These stocks are testing resistance on various time frames.

Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue Of $34.4 Million And First Quarter 2014 Results

Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue Of $34.4 Million And First Quarter 2014 Results

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and...

Pacira Pharmaceuticals Announces Timing For First Quarter 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals Announces Timing For First Quarter 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company’s first quarter ended March 31, 2014, will be released before the market opens on Thursday, May 1, 2014.

Pacira Pharmaceuticals Announces Grants Of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)

Pacira Pharmaceuticals Announces Grants Of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that on April 15, 2014, it approved the grant of stock options to 17 new employees to purchase an aggregate of 81,000 shares of common stock.

Use Options For a Chance To Buy PCRX at a 28% Discount

Use Options For a Chance To Buy PCRX at a 28% Discount

Looking back to 2 days ago, Pacira Pharmaceuticals priced a 1,600,000 share secondary stock offering at $64.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Thursday, the stock is now 7.7% higher than the offering price.

Heavy Trading On Pacira Pharmaceuticals (PCRX) Before Market Open

Heavy Trading On Pacira Pharmaceuticals (PCRX) Before Market Open

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a pre-market mover with heavy volume candidate

Pacira Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Pacira Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the pricing of its previously announced public offering of 1,600,000 shares of its common stock at a public offering price of $64.

Pacira Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Pacira Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it is offering $100 million of its common stock in a proposed underwritten public offering.

Pacira Pharmaceuticals Enters Into Strategic Co-Production Partnership With Patheon To Create Additional EXPAREL Manufacturing Capacity

Pacira Pharmaceuticals Enters Into Strategic Co-Production Partnership With Patheon To Create Additional EXPAREL Manufacturing Capacity

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced entering into a strategic co-production partnership with Patheon, the pharmaceutical services business owned by DPx Holdings B.

Pacira Pharmaceuticals (PCRX) Is Today's Dead Cat Bounce Stock

Pacira Pharmaceuticals (PCRX) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

EXPAREL Use In Femoral Nerve Block For Total Knee Arthroplasty Further Supported By Additional Data From Phase 3 Pivotal Study, SNDA Submission Planned For Second Quarter 2014

EXPAREL Use In Femoral Nerve Block For Total Knee Arthroplasty Further Supported By Additional Data From Phase 3 Pivotal Study, SNDA Submission Planned For Second Quarter 2014

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) to achieve a femoral nerve ...

Pacira Pharmaceuticals, Inc. Announces FDA Approval Of Additional Manufacturing Suite For EXPAREL

Pacira Pharmaceuticals, Inc. Announces FDA Approval Of Additional Manufacturing Suite For EXPAREL

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.

Two New Studies Support Use Of EXPAREL For Postsurgical Pain Management Following Total Joint Replacement

Two New Studies Support Use Of EXPAREL For Postsurgical Pain Management Following Total Joint Replacement

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data evaluating the use of EXPAREL ® (bupivacaine liposome injectable suspension) to manage postsurgical pain following total joint...

TheStreet Quant Rating: C (Hold)